COMP <GO>
SIBN vs IART // EV/EBITDA & P/E VALUATION
SI-BONE Inc. (NASDAQ) VS. Integra LifeSciences Holdings Corporation (NASDAQ) • 15-METRIC TALLY: SIBN 10
— IART 0
■ METRIC PARITY
LAST: $22.41 (+2.66%) • MKT CAP: $1.00B
valuation
—
LAST: $12.83 (+4.82%) • MKT CAP: $998.2M
valuation
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (SIBN VS. IART)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | SIBN | IART | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 79.60% | 50.90% | +28.70 | SIBN | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -10.30% | -35.00% | +24.70 | SIBN | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -0.90% | -3.11% | +2.21 | SIBN | /fcf-yield <GO> |
| Operating Margin | -11.10% | -30.20% | +19.10 | SIBN | /operating-margins <GO> |
| Net Profit Margin | -9.40% | -31.60% | +22.20 | SIBN | /net-margins <GO> |
| Revenue Growth (YoY) | 20.20% | 1.50% | +18.70 | SIBN | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 8.73 | 0.64 | +8.09 | SIBN | /balance-sheet <GO> |
| Piotroski F-Score Quality | 6/9 | 4/9 | +2.00 | SIBN | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 58.6 | 42.8 | +15.83 | SIBN | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $1.00B | $998.2M | $6.2M | SIBN | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | SIBN REV | IART REV | SIBN GROSS % | IART GROSS % | SIBN FCF | IART FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $200.9M | $1.64B | 79.6% | 50.9% | -$9.1M | -$31.1M |
| FY 2024 | $167.2M | $1.61B | 79.0% | 54.8% | -$22.9M | $25.0M |
| FY 2023 | $138.9M | $1.54B | — | — | -$18.7M | $140.0M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
SIBN // BETA —
IART // BETA —